Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$4.2 million.

  • Vivos Therapeutics' Cash from Operations changed 0.0% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.4 million, marking a year-over-year decrease of 1477.76%. This contributed to the annual value of -$12.7 million for FY2024, which is 631.17% down from last year.
  • As of Q3 2025, Vivos Therapeutics' Cash from Operations stood at -$4.2 million, which was down 0.0% from -$3.5 million recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Cash from Operations ranged from a high of -$2.5 million in Q1 2024 and a low of -$6.1 million during Q1 2022
  • Its 5-year average for Cash from Operations is -$3.8 million, with a median of -$3.7 million in 2021.
  • In the last 5 years, Vivos Therapeutics' Cash from Operations tumbled by 79263.23% in 2021 and then soared by 5217.76% in 2023.
  • Vivos Therapeutics' Cash from Operations (Quarter) stood at -$4.1 million in 2021, then grew by 27.22% to -$3.0 million in 2022, then grew by 8.47% to -$2.7 million in 2023, then decreased by 5.61% to -$2.9 million in 2024, then plummeted by 44.83% to -$4.2 million in 2025.
  • Its Cash from Operations stands at -$4.2 million for Q3 2025, versus -$3.5 million for Q2 2025 and -$3.8 million for Q1 2025.